The ACC/AHA Task Force on Practice Guidelines (Task Force), whose charge is to develop, update, or revise practice guidelines for cardiovascular diseases and procedures, directs this effort. The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the production of guidelines in the area of cardiovascular disease since 1980. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist clinicians in selecting the best management strategy for an individual patient. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. Initial Clinical Evaluation in Patients With AFe76 Reviewer Relationships With Industry and Other Entities (Relevant)e68 Postoperative Cardiac and Thoracic Surgery: Recommendationse51Įvidence Gaps and Future Research Directionse52Īuthor Relationships With Industry and Other Entities (Relevant)e66 WPW and Pre-Excitation Syndromes: Recommendationse49 Hypertrophic Cardiomyopathy: Recommendationse45 Surgical Maze Procedures: Recommendationse44 Pacemakers and Implantable Cardioverter-Defibrillators for Prevention of AFe43 Outpatient Initiation of Antiarrhythmic Drug Therapye40ĪF Catheter Ablation to Maintain Sinus Rhythm: Recommendationse41 6.3.1.Ĭomplications Following AF Catheter Ablatione43 Pharmacological Agents for Preventing AF and Maintaining Sinus Rhythme35 6.2.1.Īntiarrhythmic Drugs to Maintain Sinus Rhythm: Recommendationse35 6.2.1.1. Pharmacological Cardioversion: Recommendationse33 Prevention of Thromboembolism: Recommendationse33ĭirect-Current Cardioversion: Recommendationse33 Selecting and Applying a Rate-Control Strategye31 5.3.1.Įlectrical and Pharmacological Cardioversion of AF and Atrial Fluttere33 6.1.1. Other Pharmacological Agents for Rate Controle30 ![]() Nondihydropyridine Calcium Channel Blockerse29 Specific Pharmacological Agents for Rate Controle29 5.1.1. Percutaneous Approaches to Occlude the LAAe26Ĭardiac Surgery-LAA Occlusion/Excision: Recommendatione26 Nonpharmacological Stroke Preventione26 4.4.1. Interruption and Bridging Anticoagulatione25 ![]() New Target-specific Oral Anticoagulantse22Ĭonsiderations in Selecting Anticoagulantse23 Risk Stratification Schemes (CHADS 2, CHA 2DS 2-VASc, and HAS-BLED)e17 Selecting an Antithrombotic Regimen-Balancing Risks and Benefitse17 4.1.1.1. Risk-Based Antithrombotic Therapy: Recommendationse15 4.1.1. Risk Factors and Associated Heart Diseasee13Ĭlinical Evaluation: Recommendatione14 3.1.īasic Evaluation of the Patient With AFe14 3.1.1.Ĭlinical History and Physical Examinatione14 The Renin-Angiotensin-Aldosterone Systeme13 Pathophysiological Mechanismse13 2.2.3.1. ![]() Mechanisms of AF and Pathophysiologye11 2.2.1.Įlectrophysiological Mechanismse12 2.2.2.1. Definitions and Pathophysiology of AFe8 2.1.1.Ītrial Flutter and Macroreentrant Atrial Tachycardiae9
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |